Susceptibility of Pseudomonas isolates from the ears and skin of dogs to enrofloxacin, marbofloxacin, and ciprofloxacin.
The purpose of this study was to compare susceptibilities of ear and skin Pseudomonas spp. isolates to enrofloxacin, marbofloxacin, and ciprofloxacin. Specimens were obtained from dogs examined in a veterinary dermatology referral hospital. Susceptibilities of ear isolates to enrofloxacin, marbofloxacin, and ciprofloxacin were 46.9%, 66.7%, and 75.0%, respectively. Susceptibilities of skin isolates to the same drugs were 76.2%, 81.0%, and 80.0%, respectively. Ear isolates were significantly less susceptible to enrofloxacin than to ciprofloxacin (P=0.021), and ear isolates were significantly less susceptible to enrofloxacin than were skin isolates (P=0.034). When fluoroquinolone resistance was present, ear isolates were significantly less susceptible to enrofloxacin than to ciprofloxacin (P<0.001) and marbofloxacin (P=0.014).
Wildermuth
Brett Everett
BE
Animal Dermatology Clinic, 5610 Kearny Mesa Road, Suite B1, San Diego, California 92111, USA.
Griffin
Craig E
CE
Rosenkrantz
Wayne S
WS
Boord
Mona J
MJ
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy* / Q000382:microbiology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D000077422:Enrofloxacin; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D010032:Otitis Externa / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D011549:Pseudomonas / Q000187:drug effects*; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D011711:Pyoderma / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary; D015363:Quinolones / Q000627:therapeutic use; D012189:Retrospective Studies; D017192:Skin Diseases, Bacterial / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin; D002939:Ciprofloxacin; C080260:marbofloxacin